Pharmafile Logo
Pharmafocus logo
Advanced Search

Shire

Showing 15 posts of 170 posts found.

Shire says new plant will add to Replagal, Vpriv capacity

January 17, 2011
Manufacturing and Production Cerezyme, Replagal, Shire, Vpriv

UK drugmaker Shire has completed construction of a new manufacturing facility for its orphan disease drugs Replagal and Vpriv, and …

News
Pfizer headquarters

Pfizer submits Gaucher drug to EMA

November 29, 2010
Sales and Marketing Cerezyme, EMA, Gaucher disease, Genzyme, Pfizer, Protalix BioTherapeutics, Shire, Vpriv, taliglucerase alfa

Pfizer and partner Protalix BioTherapeutics have submitted a marketing application to European regulator the EMA for their Gaucher disease candidate …

News

Philip Vickers joins Shire

October 13, 2010
Research and Development Shire, appointment, research and development

Shire has appointed Philip Vickers as senior VP of research and development for its Human Genetic Therapies (HGT) business. He …

Appointment
FDA

FDA already notified on ProAmatine withdrawal, says Shire

August 18, 2010
Sales and Marketing FDA, ProAmatine, Shire

Shire is to withdraw its product ProAmatine following a demand from the FDA early this week regarding post-marketing data on …

News

FDA considers pulling ProAmantine

August 17, 2010
Sales and Marketing FDA, Shire, post-marketing

Shire’s low blood pressure drug ProAmantine and generic copies could be withdrawn from the US market because no post-marketing studies …

News

Shire profits from Genzyme woes

August 5, 2010
Sales and Marketing Shire

Specialist pharma company Shire has posted a set of strong results, thanks in part to the gains it has made …

News

Shire moves in on Movetis

August 5, 2010
Research and Development, Sales and Marketing Movetis, Shire

Shire has made a €428 million offer for Belgium-based Movetis in a bid to grow its business in Europe and …

News

Shire’s Vpriv recommended for European approval

June 28, 2010
Sales and Marketing Brinavess, Gaucher, Rapiscan, Ruconest, Shire, Sycrest

Shire has won backing from a key European regulatory committee for its new Gaucher disease orphan drug. Vpriv was one …

News

Working Life: Jo Ferdinando

June 22, 2010
Manufacturing and Production, Research and Development Shire, Working Life, careers

How did you find your way into your most current role? After completing a BSc in Microbiology and Virology at …

Feature

Shire revenue dips after generic Adderall hit

April 30, 2010
Sales and Marketing Adderall, Fabrazyme, Gaucher's, Shire

Shire’s first quarter revenues fell by 5% after its ADHD treatment Adderall XR succumbed to generic competition from Teva.  This …

News
William Burns

Bill Burns joins Shire board

March 17, 2010
Research and Development, Sales and Marketing Shire, appointment, research and development, sales and marketing

Former Roche pharma chief executive Bill Burns has joined the board at Shire as a non-executive director. Burns has also …

Appointment

Shire launches Vpriv to capitalise on Genzyme woes

March 2, 2010
Sales and Marketing Cerezyme, Gaucher's, Shire

Shire has gained US approval to launch Vpriv, its new treatment for Gaucher’s disease, which it hopes will steal market …

News

Shire readies Gaucher drug Vpriv

February 23, 2010
Manufacturing and Production Cerezyme, Gaucher's, Shire, Vpriv

Shire Pharmaceuticals says it has already manufactured enough of its Vpriv to treat around 400 Gaucher disease patients and could …

News
Shire's Adderall

Low Adderall sales hit Shire

February 22, 2010
Sales and Marketing 2009 financials, Adderall, Shire

Shire has posted negative growth due to generic competition for its flagship ADHD drug Adderall XR. Product sales were down …

News
Shire's ADHD website

Digital Pharma: Byte-sized roundup

January 8, 2010
Medical Communications Diabetes UK, NICE, Shire, ViiV, digital pharma, doctors.net, iphone

Includes online petition against NICE decision, Shire brings ADHD to Twitter, ViiV joins Twitter, Doctors.net.uk launches iPhone app and Diabetes …

News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026